→
info@praetego.com

In the United States, 1 in 3 people are at risk for serious and life threatening complications from glucose dysregulation, such as diabetes. Praetego is an early stage pharmaceutical company focused on protecting these patients. Our drug candidates are designed to limit disease progression.

Learn More
↓

Praetego’s first Amadorin, PimoxIV, is an intravenous (IV) infusion drug candidate to mitigate COVID-19 kidney risk.

1. Amadorins

Praetego’s novel small molecules (the Amadorins) offer the possibility of systemic protection from glucose damage. Treatment with an Amadorin could radically improve the health of diabetic and pre-diabetic patients.  

Glucose fuels a non-enzymatic process that damages proteins and leads to harmful byproducts called Advanced Glycation end-products, or AGEs. AGE accumulation can damage small blood vessels in the eyes, kidneys, and that support the nerves in our extremities. This mechanism of damage is present across the spectrum of serious diabetic complications as well as cardiovascular disease and neurodegeneration.

The Amadorins, developed through a proprietary assay, inhibit AGE formation at its earliest stages. By interrupting the cascade at the first step of oxidative breakdown, Amadorins offer the greatest promise of protection by limiting disease progression. As we optimized our candidates for future clinical utility, we improved potency, safety, and pharmacological properties.

For the millions of people living with diabetes, the Amadorins were developed to halt disease progression, rather than manage symptoms.

2. Development Programs

PimoxIV for COVID-19 Acute Kidney Injury

Under IND# 143,097, PIMOXIV (pyridoxamine dihydrochloride) is an intravenous formulation to protect patients from acute kidney injury (AKI) following cardiac surgery. Praetego is encouraged by FDA communications in support of a program revision to COVID-19 AKI.

PimoxIV’s active ingredient, pyridoxamine, effectively inhibits a cascade of pathogenic oxidative chemistries that develops in patients with diabetes and lead to irreversible kidney damage.  These same chemistries have been observed in acute kidney injury (AKI). For patients with comorbidities such as diabetes at increased risk of COVID-19 complications, PimoxIV is a clinic-ready candidate that could mitigate the risks to this patient population.

Diabetic Peripheral Neuropathy (DPN)

DPN is the damage that effects the nerves in the hands and feet of diabetics. About 50% of diabetics develop DPN. For many it eventually causes pain. Praetego’s Amadorins target the cause of the damage.
‍
In a proof of concept study using a standard animal model of DPN, the Amadorins restored nerve function. They reversed nerve deficits in both large and small nerve fibers. Over the series of Amadorins tested, we confirmed that stronger AGE inhibition meant greater potency in the preclinical model of diabetic peripheral neuropathy. In preclinical safety studies, the Amadorins demonstrated a wide therapeutic window and minimal off-target hits.
‍

Other Serious Diabetic Complications

Beyond DPN, we are targeting Cognitive Decline, Nephropathy (Chronic Kidney Disease) and other serious diabetic complications.

3. Company

Praetego was founded in 2017 in Durham, North Carolina.

Management

Our leadership team pioneered the research leading to the discovery of Amadorins and offers extensive technical and operational experience in developmental stage drug companies.

Pepper Landson
CEO & Co-Founder

Pepper Landson is a 28-year pharma veteran. She has a proven record of creating value in early stage companies. Combining her skills in business development and operations with an extensive drug development background, she is ideally suited to her role. She has worked exclusively on the Amadorin technology and diabetic complications for the last 8 years.

Raja G. Khalifah, PhD
Chief Scientific Officer

Raja G. Khalifah, PhD, is a broadly trained chemist and biochemist who transitioned from academia to directing research at three startups founded on discoveries from his research. Experienced in medicinal chemistry and drug design, pharmacokinetics and drug metabolism, and preclinical and clinical studies. Primary co-inventor on 15 issued US patents in Amadorins and related fields.

Peter C. Johnson, MD
Chief Medical Officer

Peter C. Johnson, MD, is both an accomplished surgeon and clinical researcher. His career is complemented by successful entrepreneurial endeavors in the space of regenerative medicine and biomedical technology.

Paul A. Boyer
‍‍Chief Financial Officer

Paul A. Boyer is seasoned financial executive with experience in the field of diabetes. He is a proven value creator in start-ups, high-growth, and VC/private equity ventures for public & private companies. He has executed ~$1B in public & private equity & debt, including a successful IPO. He also developed/orchestrated 16 M&A’s.

Advisory Board

Our Advisory Board includes world renowned experts providing guidance across the spectrum of diabetic complications.

Rayaz Malik, MD, PhD
Neuropathy

Weill Cornell School of Medicine

Peter McCullough, MD, MPH
Cardio-Renal

Baylor University Medical Center

George Bakris, MD
Nephropathy & Hypertension

University of Chicago

Jamie Dwyer, MD
Nephrology

Vanderbilt University Medical Center

Alexander ‘Zan’ Fleming, MD
Metabolic Disease & Regulatory Strategy

Former head of the Division of Metabolic and Endocrinology Products, U.S. FDA

4. News

Praetego to present at the Venture Connect Summit in Raleigh NC

March 1, 2020
Praetego will showcase their candidates as potential disease modifying drugs against serious diabetic complications, starting with Diabetic Peripheral Neuropathy. The Amadorins are novel small molecules developed by Praetego scientists and designed from a clinically proven prototype.
↗
February 10, 2020
Praetego co-founder and CEO Pepper Landson sat down with Proactive’s Christine Corrado at BIO CEO in New York. The Durham, North Carolina-based preclinical-stage pharmaceutical company is focusing on developing treatments to address serious diabetic complications.
↗

Praetego submits a $2.5M Phase 2 grant to NIH/NIDDK

January 2, 2020
After a successful conclusion of the Phase 1 NIDDK grant, Praetego submits a Phase 2 SBIR/STTR grant to continue preclinical development of novel Amadorins against Diabetic Peripheral Neuropathy. This award would provide preclinical proof of concept in multiple animal models of Type 1 and Type 2 diabetic neuropathy.

5. Contact

Address
68 TW Alexander Drive
Durham, NC 27709

Praetego is located in the heart of Research Triangle Park, home to a robust life science ecosystem.

→
info@praetego.com
© Praetego Inc.  |  Site Design